410 related articles for article (PubMed ID: 30689920)
21. MDM4 enhances p53 stability by promoting an active conformation of the protein upon DNA damage.
Di Conza G; Mancini F; Buttarelli M; Pontecorvi A; Trimarchi F; Moretti F
Cell Cycle; 2012 Feb; 11(4):749-60. PubMed ID: 22374672
[TBL] [Abstract][Full Text] [Related]
22. MDM2 but not MDM4 promotes retinoblastoma cell proliferation through p53-independent regulation of MYCN translation.
Qi DL; Cobrinik D
Oncogene; 2017 Mar; 36(13):1760-1769. PubMed ID: 27748758
[TBL] [Abstract][Full Text] [Related]
23. FAM193A is a positive regulator of p53 activity.
Szwarc MM; Guarnieri AL; Joshi M; Duc HN; Laird MC; Pandey A; Khanal S; Dohm E; Bui AK; Sullivan KD; Galbraith MD; Andrysik Z; Espinosa JM
Cell Rep; 2023 Mar; 42(3):112230. PubMed ID: 36897777
[TBL] [Abstract][Full Text] [Related]
24. Dual Targeting of MDM4 and FTH1 by MMRi71 for Induced Protein Degradation and p53-Independent Apoptosis in Leukemia Cells.
Lama R; Galster SL; Xu C; Davison LW; Chemler SR; Wang X
Molecules; 2022 Nov; 27(22):. PubMed ID: 36431769
[TBL] [Abstract][Full Text] [Related]
25. The MDM2 gene family.
Mendoza M; Mandani G; Momand J
Biomol Concepts; 2014 Mar; 5(1):9-19. PubMed ID: 25372739
[TBL] [Abstract][Full Text] [Related]
26. CEP-1347 Targets MDM4 Protein Expression to Activate p53 and Inhibit the Growth of Glioma Cells.
Mitobe Y; Nakagawa-Saito Y; Togashi K; Suzuki S; Sugai A; Matsuda KI; Sonoda Y; Kitanaka C; Okada M
Anticancer Res; 2022 Oct; 42(10):4727-4733. PubMed ID: 36192008
[TBL] [Abstract][Full Text] [Related]
27. Targeting the MDM2/MDM4 interaction interface as a promising approach for p53 reactivation therapy.
Pellegrino M; Mancini F; Lucà R; Coletti A; Giacchè N; Manni I; Arisi I; Florenzano F; Teveroni E; Buttarelli M; Fici L; Brandi R; Bruno T; Fanciulli M; D'Onofrio M; Piaggio G; Pellicciari R; Pontecorvi A; Marine JC; Macchiarulo A; Moretti F
Cancer Res; 2015 Nov; 75(21):4560-72. PubMed ID: 26359458
[TBL] [Abstract][Full Text] [Related]
28. The MDM2 RING domain and central acidic domain play distinct roles in MDM2 protein homodimerization and MDM2-MDMX protein heterodimerization.
Leslie PL; Ke H; Zhang Y
J Biol Chem; 2015 May; 290(20):12941-50. PubMed ID: 25809483
[TBL] [Abstract][Full Text] [Related]
29. Loss of oocytes due to conditional ablation of Murine double minute 2 (Mdm2) gene is p53-dependent and results in female sterility.
Livera G; Uzbekov R; Jarrier P; Fouchécourt S; Duquenne C; Parent AS; Marine JC; Monget P
FEBS Lett; 2016 Aug; 590(16):2566-74. PubMed ID: 27364741
[TBL] [Abstract][Full Text] [Related]
30. Synergistic roles of Mdm2 and Mdm4 for p53 inhibition in central nervous system development.
Xiong S; Van Pelt CS; Elizondo-Fraire AC; Liu G; Lozano G
Proc Natl Acad Sci U S A; 2006 Feb; 103(9):3226-31. PubMed ID: 16492743
[TBL] [Abstract][Full Text] [Related]
31. Lithocholic acid is an endogenous inhibitor of MDM4 and MDM2.
Vogel SM; Bauer MR; Joerger AC; Wilcken R; Brandt T; Veprintsev DB; Rutherford TJ; Fersht AR; Boeckler FM
Proc Natl Acad Sci U S A; 2012 Oct; 109(42):16906-10. PubMed ID: 23035244
[TBL] [Abstract][Full Text] [Related]
32. Widespread overexpression of epitope-tagged Mdm4 does not accelerate tumor formation in vivo.
De Clercq S; Gembarska A; Denecker G; Maetens M; Naessens M; Haigh K; Haigh JJ; Marine JC
Mol Cell Biol; 2010 Nov; 30(22):5394-405. PubMed ID: 20855528
[TBL] [Abstract][Full Text] [Related]
33. Analysis of human MDM4 variants in papillary thyroid carcinomas reveals new potential markers of cancer properties.
Prodosmo A; Giglio S; Moretti S; Mancini F; Barbi F; Avenia N; Di Conza G; Schünemann HJ; Pistola L; Ludovini V; Sacchi A; Pontecorvi A; Puxeddu E; Moretti F
J Mol Med (Berl); 2008 May; 86(5):585-96. PubMed ID: 18335186
[TBL] [Abstract][Full Text] [Related]
34. Mitochondrial MDM4 (MDMX): an unpredicted role in the p53-mediated intrinsic apoptotic pathway.
Mancini F; Moretti F
Cell Cycle; 2009 Dec; 8(23):3854-9. PubMed ID: 19887911
[TBL] [Abstract][Full Text] [Related]
35. Polo-like kinase-1 phosphorylates MDM2 at Ser260 and stimulates MDM2-mediated p53 turnover.
Dias SS; Hogan C; Ochocka AM; Meek DW
FEBS Lett; 2009 Nov; 583(22):3543-8. PubMed ID: 19833129
[TBL] [Abstract][Full Text] [Related]
36. High levels of the p53 inhibitor MDM4 in head and neck squamous carcinomas.
Valentin-Vega YA; Barboza JA; Chau GP; El-Naggar AK; Lozano G
Hum Pathol; 2007 Oct; 38(10):1553-62. PubMed ID: 17651783
[TBL] [Abstract][Full Text] [Related]
37. Downregulation of Mdm2 and Mdm4 enhances viral gene expression during adenovirus infection.
Yang H; Zheng Z; Zhao LY; Li Q; Liao D
Cell Cycle; 2012 Feb; 11(3):582-93. PubMed ID: 22262167
[TBL] [Abstract][Full Text] [Related]
38. Dual inhibition of MDMX and MDM2 as a therapeutic strategy in leukemia.
Carvajal LA; Neriah DB; Senecal A; Benard L; Thiruthuvanathan V; Yatsenko T; Narayanagari SR; Wheat JC; Todorova TI; Mitchell K; Kenworthy C; Guerlavais V; Annis DA; Bartholdy B; Will B; Anampa JD; Mantzaris I; Aivado M; Singer RH; Coleman RA; Verma A; Steidl U
Sci Transl Med; 2018 Apr; 10(436):. PubMed ID: 29643228
[TBL] [Abstract][Full Text] [Related]
39. Simultaneous measurement of p53:Mdm2 and p53:Mdm4 protein-protein interactions in whole cells using fluorescence labelled foci.
Frosi Y; Inoue K; Ramlan SR; Lane DP; Watanabe T; Brown CJ
Sci Rep; 2019 Nov; 9(1):17933. PubMed ID: 31784573
[TBL] [Abstract][Full Text] [Related]
40. A site-directed mutagenesis study of the MdmX RING domain.
Egorova O; Mis M; Sheng Y
Biochem Biophys Res Commun; 2014 May; 447(4):696-701. PubMed ID: 24755078
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
